

INPLASY PROTOCOL

To cite: Fahmy et al. Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic review and meta-analysis. Inplasy protocol 202250048. doi: 10.37766/inplasy2022.5.0048

Received: 09 May 2022

Published: 09 May 2022

Corresponding author:
Omar Fahmy

omarfahmy.ahmed@upm.edu.my

Author Affiliation:
Universiti Putra Malaysia.

Support: King Abdulaziz
University.

Review Stage at time of this submission: Completed but not published.

Conflicts of interest:
None declared.

Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic review and meta-analysis

Fahmy, O¹; Nabil, A²; Usama, A³; Giuseppe, C⁴.

Review question / Objective: Is combined durvalumab and tremelimumab therapy associated with more side effects compared to durvalumab monotherapy?

Participant or population: Patients with solid cancers.

Main outcome(s): Combination therapy is associated with more side effects and discontinuation rates.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 09 May 2022 and was last updated on 09 May 2022 (registration number INPLASY202250048).

INTRODUCTION

Review question / Objective: Is combined durvalumab and tremelimumab therapy associated with more side effects compared to durvalumab monotherapy?

Condition being studied: Side effects and tolerability, discontinuation rates, mortality rates.

METHODS

Participant or population: Patients with solid cancers.

Intervention: Patients who received monotherapy compared to those who received combination therapy.

Comparator: Patients who received monotherapy compared to those who received combination therapy.

Study designs to be included: Randomized controlled trials.

Eligibility criteria: Randomized controlled trials.

Information sources: Electronic databases.

Main outcome(s): Combination therapy is associated with more side effects and discontinuation rates.

Quality assessment / Risk of bias analysis: Using RevMan 5.4 software.

Strategy of data synthesis: Using RevMan 5.4 software.

Subgroup analysis: Using RevMan 5.4 software.

Sensitivity analysis: Using RevMan 5.4 software.

Country(ies) involved: Malaysia.

Keywords: Durvalumab, Tremelimumab, Side effects, cancer.

Contributions of each author:

Author 1 - Omar Fahmy.

Author 2 - Nabil Alhakamy.

Author 3 - Usama Ahmed.

Author 4 - Giuseppe Caruso.